RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
For large libraries of small molecules, exhaustive combinatorial chemical screens become infeasible to perform when considering a range of disease models, assay conditions, and dose ranges. Deep learning models have achieved state of the art results in silico for the prediction of synergy scores. However, databases of drug combinations are biased towards synergistic agents and these results do not necessarily generalise out of distribution. We employ a sequential model optimization search utilising a deep learning model to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation. Our small scale wet lab experiments only account for evaluation of ~5% of the total search space. After only 3 rounds of ML-guided in vitro experimentation (including a calibration round), we find that the set of drug pairs queried is enriched for highly synergistic combinations; two additional rounds of ML-guided experiments were performed to ensure reproducibility of trends. Remarkably, we rediscover drug combinations later confirmed to be under study within clinical trials. Moreover, we find that drug embeddings generated using only structural information begin to reflect mechanisms of action. Prior in silico benchmarking suggests we can enrich search queries by a factor of ~5-10x for highly synergistic drug combinations by using sequential rounds of evaluation when compared to random selection, or by a factor of >3x when using a pretrained model selecting all drug combinations at a single time point.
Code (1)
Tasks
BenchmarkingModel OptimizationSimilar Papers 제목 키워드 기반
Open Droplet Microfluidics for Testing Multi-Drug Resistance and Antibiotic Resilience in Bacteria
New combinations of existing antibiotics are being investigated to combat bacterial resilience. This requires detection technologies with reasonable cost, accuracy, resolution, and throughput. Here, we present a multi -d…
Automated Drug-Related Information Extraction from French Clinical Documents: ReLyfe Approach
Structuring medical data in France remains a challenge mainly because of the lack of medical data due to privacy concerns and the lack of methods and approaches on processing the French language. One of these challenges …
ManagementOptimal switching strategies in multi-drug therapies for chronic diseases
Antimicrobial resistance is a threat to public health with millions of deaths linked to drug resistant infections every year. To mitigate resistance, common strategies that are used are combination therapies and therapy …
Discovering Drug-Drug and Drug-Disease Interactions Inducing Acute Kidney Injury Using Deep Rule Forests
Patients with Acute Kidney Injury (AKI) increase mortality, morbidity, and long-term adverse events. Therefore, early identification of AKI may improve renal function recovery, decrease comorbidities, and further improve…
TorchDrug: A Powerful and Flexible Machine Learning Platform for Drug Discovery
Machine learning has huge potential to revolutionize the field of drug discovery and is attracting increasing attention in recent years. However, lacking domain knowledge (e.g., which tasks to work on), standard benchmar…
BIG-bench Machine LearningDrug DiscoveryMolecular Property PredictionProperty Prediction